Exchange: NASDAQ·Updated 07:38 PM EST

ORKA News

News
all
press releases
Oruka Therapeutics (NASDAQ:ORKA) Insider Joana Goncalves Sells 7,000 Shares of Company Stock
Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) insider Joana Goncalves sold 7,000 shares of the firm's stock in a transaction on Monday, November 16th. The stock was sold at an average price of $100.96, for a total value of $706,720.00. Following the completion of the transaction, the...
MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Insider Joana Goncalves Sells 7,000 Shares of Company Stock
Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) insider Joana Goncalves sold 7,000 shares of the firm's stock in a transaction on Monday, November 16th. The stock was sold at an average price of $100.96, for a total value of $706,720.00. Following the completion of the transaction, the...
MarketBeat
More News
Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) Director Kristine Ball sold 18,000 shares of the company's stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $104.93, for a total transaction of $1,888,740.00. Following the...
MarketBeat
Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) SVP Arjun Agarwal sold 10,000 shares of the firm's stock in a transaction on Thursday, November 12th. The stock was sold at an average price of $104.97, for a total transaction of $1,049,700.00. Following the transaction, the senior vice...
MarketBeat
U.S. stocks rose; Dow gained 350 points. Range Resources jumped 15% on EQT acquisition, while Surgery Partners and others posted sharp gains.read more...
Benzinga
Oruka's ORKA-001 delivers deeper psoriasis clearance at week 28, but safety disclosures may have weighed on shares despite positive efficacy data.
Zacks
Oruka's three-month rally reflects investor confidence in ORKA-001, with key clinical data and pipeline milestones scheduled ahead.
Zacks
PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.
Zacks
Oruka Therapeutics stock falls after hours after Fairmount sells a $300 million stake via SEC filing.read more...
Benzinga
Key PointsAn Oruka Therapeutics executive reported selling 9,854 directly held Common Stock shares for a total value of $687K based on a weighted average price of $69.72 per share as of June 15, 2026...
Nasdaq News: Markets
Key PointsArjun Agarwal sold 10,290 shares for a transaction value of approximately ~$608,000, based on a weighted average price of $59.07 per share on May 18, 2026...
Nasdaq News: Markets

Advertisement|Remove ads.